MedTrace Logo

EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]

NCT02922088 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2964

Last updated 2021-03-18

No results posted yet for this study

Summary

The DuraGraft® Registry is a European registry of patients who have undergone CABG and whose vascular grafts have been treated with DuraGraft. All participating sites will be from countries in Europe. The DuraGraft Registry will collect pre-CABG, intraoperative and post-operative data, major post-CABG cardiovascular adverse events, health economic outcomes and patient reported quality of life over a period of 5 years.

Conditions

Interventions

DEVICE

DuraGraft

DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.

Sponsors & Collaborators

  • Somahlution LLC

    lead INDUSTRY

Principal Investigators

  • Maximillian Emmert, MD · University Hospital, Zürich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-09
Primary Completion
2024-08-31
Completion
2024-12-31

Countries

  • Austria
  • Germany
  • Ireland
  • Italy
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922088 on ClinicalTrials.gov